Cajal Neuroscience

company

About

Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.

Details

Last Funding Type
Series A
Last Funding Money Raised
$96M
Industries
Biotechnology,Neuroscience,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2020
Number Of Employee
101 - 250
Operating Status
Active

Cajal Neuroscience is a biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. The company combines a suite of state-of-the-art approaches and technologies, including integrative human genetics and multi-omics, high-throughput functional genomics, and advanced microscopy, to accelerate neurodegeneration target and drug discovery.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$96M
Cajal Neuroscience has raised a total of $96M in funding over 2 rounds. Their latest funding was raised on Nov 29, 2022 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 29, 2022 Series A $96M 7 Lux Capital
The Column Group
Detail
Jan 1, 2020 Seed 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
7
Cajal Neuroscience is funded by 7 investors. Lux Capital and The Column Group are the most recent investors.
Investor Name Lead Investor Funding Round
Lux Capital Yes Series A
The Column Group Yes Series A
Alexandria Venture Investments Series A
Bristol Myers Squibb Series A
Dolby Family Ventures Series A
Evotec Series A
Two Sigma Ventures Series A

Employee Profiles

Number of Employee Profiles
10
Cajal Neuroscience has 10 current employee profiles, including Board member Josh Wolfe
Board member
Board member
Executive
Board member